Nicholas Weiant

Day trader with 10 years of experience |Expert at selling early | Turned $500 into $400k. Verified -
Fitness&nutrition enthusiast.

[Nicholas Weiant @FourLeafTrader1]

@edu_trades @veptrader @Kinfo Might have to hop in. Not in a community right now and missing out

[Nicholas Weiant @FourLeafTrader1]

@moonmarket Same. This one might just trap shorts.

[Nicholas Weiant @FourLeafTrader1]

@AT09_Trader This is awesome. Great stuff

[TheChartGuys @ChartGuys]

I have a confession.
I dont care at all about the Space X IPO.
Does that make me a bad person?

[Nicholas Weiant @FourLeafTrader1]

@ChartGuys I love this and more people should be just completely ignoring it. It’s not what real traders do. If you’re a successful trader with years of practice you avoid plays like this one.

[Nicholas Weiant @FourLeafTrader1]

@DekmarTrades The ones making money on these are NOT the seasoned good trades. Only traders that are blindly buying and getting lucky. No point in chases these with any sort of size

[Nicholas Weiant @FourLeafTrader1]

@OddStockTrader These random runners actually make it more difficult to trade.

[Nicholas Weiant @FourLeafTrader1]

@saylor 🤦🏼‍♂️

[Nicholas Weiant @FourLeafTrader1]

@CoachDanGo I do it every leg day. Not a single person in the gym does it. Probably the most brutal but most effective.

[Nicholas Weiant @FourLeafTrader1]

@moonmarket @TT_stocks_ Exactly. I think the PDT removal is overhyped right now.

[Nicholas Weiant @FourLeafTrader1]

@moonmarket $HTCR

[Nicholas Weiant @FourLeafTrader1]

@TT_stocks_ They also release a ton of news so that will definitely help it squeeze.

[Nicholas Weiant @FourLeafTrader1]

@EdgeToTrade This is very helpful. Great trading app!

[Nicholas Weiant @FourLeafTrader1]

@paulsaladinomd Agreed. This is not living.

[Nicholas Weiant @FourLeafTrader1]

@TT_stocks_ Sick!

[Nicholas Weiant @FourLeafTrader1]

$OTLK wow. He nailed it. @TT_stocks_

[Nicholas Weiant @FourLeafTrader1]

$AIM 👀

[TheBull @TheBull_Stocks]

$AIM 0.2635 could follow! $SBFM $GOVX soaring! $AIM hasn't and fits the theme!
AIM ImmunoTech is actively developing its investigational drug, Ampligen (rintatolimod), as a potential prophylactic and early-onset therapy for Ebola virus disease (EVD). Pre-clinical studies have shown that the drug offers 100% protection in lethal Ebola mouse infection models

[Nicholas Weiant @FourLeafTrader1]

@SarwanJohn 100%. been following $MGN for a month and shocked it’s still not run yet

[Nicholas Weiant @FourLeafTrader1]

@SarwanJohn Love this one too!

[Nicholas Weiant @FourLeafTrader1]

@TT_stocks_ 👀